Literature DB >> 17222212

Immunohistochemical detection of myogenin and p21 in methylcholanthrene-induced mouse rhabdomyosarcomas.

Makoto Inoue1, Haiyan Wu.   

Abstract

3-Methylcholanthrene (MC)-induced 10 embryonal (ERSs) and 24 pleomorphic rhabdomyosarcomas (PRSs) of the dermis in mouse were examined immunohistochemically for myogenin, p21 and proliferating cell nuclear antigen (PCNA) nuclear reactivity and myosin reactivity. ERSs had higher expression of myogenin and p21 compared with that of myosin. PRSs were divided into two groups having high (moderate or marked reactivity; HLM) and low (mild reactivity; LLM) levels of myosin expression. Expression of p21 was higher in HLM-PRSs than in LLM-PRSs. Statistically significant association was observed between myosin and p21 expression in PRSs, but not between myosin and myogenin expression. Myogenin and p21 reactivity were observed in myoblast-like cells, but rarely in multinucleated cells. In ERSs, small undifferentiated myogenic precursor cells were also positive for p21. No difference of PCNA reactivity was observed between HLM-PRSs and LLM-PRSs, although its reactivity was higher in PRSs than in ERSs. The results suggest that myogenin is related to myoblast-like cell differentiation in PRSs and that p21 plays essential roles in myotube formation and myosin expression. In ERSs, p21 may be involved in inhibition of myogenic precursor cell proliferation and differentiation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17222212      PMCID: PMC2517386          DOI: 10.1111/j.1365-2613.2006.00499.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  25 in total

Review 1.  Pathologic classification of rhabdomyosarcomas and correlations with molecular studies.

Authors:  D M Parham
Journal:  Mod Pathol       Date:  2001-05       Impact factor: 7.842

2.  Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers.

Authors:  M A Furlong; T Mentzel; J C Fanburg-Smith
Journal:  Mod Pathol       Date:  2001-06       Impact factor: 7.842

3.  Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.

Authors:  M H Cessna; H Zhou; S L Perkins; S R Tripp; L Layfield; C Daines; C M Coffin
Journal:  Am J Surg Pathol       Date:  2001-09       Impact factor: 6.394

Review 4.  MyoD1 and myogenin expression in human neoplasia: a review and update.

Authors:  Andrew L Folpe
Journal:  Adv Anat Pathol       Date:  2002-05       Impact factor: 3.875

5.  Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation.

Authors:  M Thomas; B Langley; C Berry; M Sharma; S Kirk; J Bass; R Kambadur
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

6.  Myogenin--a more specific target for RT-PCR detection of rhabdomyosarcoma than MyoD1.

Authors:  Maria P Michelagnoli; Susan A Burchill; Catherine Cullinane; Peter J Selby; Ian J Lewis
Journal:  Med Pediatr Oncol       Date:  2003-01

7.  Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass.

Authors:  P Dias; B Chen; B Dilday; H Palmer; H Hosoi; S Singh; C Wu; X Li; J Thompson; D Parham; S Qualman; P Houghton
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

8.  Cell division cycle control in embryonal and alveolar rhabdomyosarcomas.

Authors:  A Moretti; A Borriello; F Monno; M Criscuolo; A Rosolen; G Esposito; R Dello Iacovo; F Della Ragione; A Iolascon
Journal:  Eur J Cancer       Date:  2002-11       Impact factor: 9.162

9.  Rhabdomyosarcoma of the head and neck in children.

Authors:  J Hicks; C Flaitz
Journal:  Oral Oncol       Date:  2002-07       Impact factor: 5.337

10.  Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis.

Authors:  V Andrés; K Walsh
Journal:  J Cell Biol       Date:  1996-02       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.